Skip to main content
. 2023 Dec 18;14(12):839. doi: 10.1038/s41419-023-06300-2

Fig. 5. Combination treatment of Imatinib (IM) and RSL3 for gastrointestinal stromal tumor (GIST) in vitro.

Fig. 5

A CCK-8 viability assay following treatment for 24 h with escalating concentrations of IM (0, 25, 50, 100, and 200 nM for T1 and 0, 50, 100, 200, and 400 nM for 882) and RSL3 (0, 0.5, 1, and 2 μM for T1 and 0, 0.25, 0.5 and 1 μM for 882) in GIST-T1 and 882 cells. B Synergy was calculated using CompuSyn and a combination index value of under 1.0 was considered synergy. C The relative GSH/GSSG ratios were assayed after GIST-T1 and 882 cells were treated with IM (50 nM for T1 and 200 nM for 882) and RSL3 (2 μM for T1 and 1 μM for 882) for 24 h. D, E Western blotting analysis of SLC7A11 and GPX4 protein expression after combination treatment of IM and RSL3 in GIST-T1 (D) and 882 cells (E) for 24 h. Experiments were independently repeated three times. Significance denoted by: ns not significant, *P < 0.05, **P < 0.01, and ***P < 0.001.